Digital Health Is Changing Health Care. Is it Changing Pharma?
Digital health presents both opportunity and threat to Big Pharma. The opportunities lie in streamlining and accelerating R&D and improving patient experience and product outcomes; the threats come from the swath of new competitors vying for a piece of the health care value pie – many with far more experience in consumer-facing services.
You may also be interested in...
Precision medicine is significantly impacting pharma dealmaking, R&D and market access, according to a new report from Datamonitor Healthcare.
Lacking revolutionary new treatment mechanisms in type 2 diabetes, pharma is relying on combinations, convenience, and beyond-the-pill services. As prices are squeezed, the winners will be those who can deliver the best-value outcomes, not necessarily those with a best-in-class drug.
Investors are piling into digital health start-ups, lured by their potential to transform inefficient health systems. Success will come, but selectively.